Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
PHAT
#2142
Phathom Pharmaceuticals, Inc. Common Stock
12.5
6
-5.92%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
-5.92%
Changement Mensuel
-11.42%
Evolution sur 6 mois
+1.05%
Changement Annuel
+119.20%
Clôture Précédente
13.3
5
Open
12.5
6
Bid
Ask
Low
12.5
6
High
12.5
6
Volume
149
Marchés
Actions des Marchés US
Soins de Santé
PHAT
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
31.32 M
31.71 M
41.97 M
58.48 M
69.64 M
78.8 M
—
Valuation ratios
Enterprise value
753.01 M
440.53 M
347.87 M
154.84 M
268.19 M
1.18 B
2.64 B
Price to earnings ratio
—
—
-2.37
-2.33
-1.53
-5.48
-11.87
Price to sales ratio
—
—
—
689.62
9.28
—
—
Price to cash flow ratio
—
—
3.2
3.42
1.92
7.25
14.69
Price to book ratio
—
—
6.27
6.46
2.02
2.76
4.31
Enterprise value to EBITDA ratio
—
—
—
-0.93
-0.97
—
—
Profitability ratios
Return on assets %
-0.44
-0.76
-1.2
-0.49
-0.88
0.85
-0.67
Return on equity %
-0.66
-1.99
-2.64
-2.77
-1.32
0.5
-0.49
Return on invested capital %
-2 378.1
-2 908.86
-12.39 K
-4 282.78
-3 385.5
1 189.71
—
Gross margin %
—
—
—
75.51
85.57
87.09
348.4
Operating margin %
—
—
—
-24.53 K
-502.18
91.36
-145.39
EBITDA margin %
—
—
—
-24.45 K
-500.75
-91
-467.77
Net margin %
—
—
—
-29.56 K
-605.09
126.35
-546.44
Liquidity ratios
Quick ratio
—
—
—
10.22
4.16
1.69
9.77
Current ratio
5.25
9.86
6.12
10.25
4.2
1.73
9.93
Inventory turnover
—
—
—
—
0.38
0.06
0.14
Asset turnover
—
—
—
0
0.14
0.55
0.66
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.13
0.47
0.58
0.33
0.53
0.81
3.18
Long term debt to total equity ratio
0.2
1.24
1.27
1.89
0.79
0.48
2.07
Per share metrics
Operating cash flow per share
—
—
3.75
2.68
4.22
2.29
2.31
EBIT per share
—
—
—
-3.26
-4.39
-2.19
-2.21
EBITDA per share
—
—
—
-3.25
-4.38
-2.19
-2.2
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
3.97
7.44
4.71
1.78
8.64
Net current asset value per share
—
—
4.1
7.75
5.7
3.14
12.67
Tangible book value per share
—
—
1.91
1.42
4.01
6.01
22.07
Working capital per share
—
—
3.43
6.99
4.34
1.33
7.3
Book value per share
—
—
1.91
1.42
4.01
6.01
22.07
Nouvelles
Guggenheim relève l’objectif de cours de Phathom à 25$ après des résultats supérieurs
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Stifel réitère sa recommandation d’achat sur Phathom, maintient l’objectif de 28$
Stifel reiterates Buy on Phathom stock, keeps $28 price target
Phathom T4 2025 : croissance du chiffre d’affaires de 217%
Phathom Q4 2025 slides: 217% revenue growth, profitability in sight
Le BPA de Phathom Pharma a dépassé les attentes de 0,34$, le CA a surpassé les prévisions
Phathom Pharma earnings beat by $0.34, revenue topped estimates
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook
Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT)